CABA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In 82 of the 91 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CABA turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.596). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RLAY saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 40 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLAY as a result. In 74 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
RLAY moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for RLAY crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
RLAY broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +19.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in 237 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 186 of 228 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.580) is normal, around the industry mean (3.596). P/E Ratio (-11.923) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CABA | RLAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 92 | 40 | |
P/E GROWTH RATING 1..100 | 10 | 44 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RLAY's Valuation (24) in the null industry is in the same range as CABA (51). This means that RLAY’s stock grew similarly to CABA’s over the last 12 months.
RLAY's Profit vs Risk Rating (100) in the null industry is in the same range as CABA (100). This means that RLAY’s stock grew similarly to CABA’s over the last 12 months.
RLAY's SMR Rating (97) in the null industry is in the same range as CABA (98). This means that RLAY’s stock grew similarly to CABA’s over the last 12 months.
RLAY's Price Growth Rating (40) in the null industry is somewhat better than the same rating for CABA (92). This means that RLAY’s stock grew somewhat faster than CABA’s over the last 12 months.
CABA's P/E Growth Rating (10) in the null industry is somewhat better than the same rating for RLAY (44). This means that CABA’s stock grew somewhat faster than RLAY’s over the last 12 months.
| CABA | RLAY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 87% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| Advances ODDS (%) | 13 days ago 88% | 13 days ago 86% |
| Declines ODDS (%) | 2 days ago 90% | 5 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CABA’s FA Score shows that 1 FA rating(s) are green while RLAY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CABA’s TA Score shows that 4 TA indicator(s) are bullish while RLAY’s TA Score has 3 bullish TA indicator(s).
CABA (@Biotechnology) experienced а -26.87% price change this week, while RLAY (@Biotechnology) price change was -10.89% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
CABA is expected to report earnings on Mar 18, 2027.
RLAY is expected to report earnings on Feb 25, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with EDIT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To CABA | 1D Price Change % | ||
|---|---|---|---|---|
| CABA | 100% | -7.32% | ||
| EDIT - CABA | 52% Loosely correlated | -4.09% | ||
| FATE - CABA | 50% Loosely correlated | -9.01% | ||
| AURA - CABA | 49% Loosely correlated | -1.58% | ||
| VIR - CABA | 48% Loosely correlated | -5.41% | ||
| NCEL - CABA | 47% Loosely correlated | -8.82% | ||
More | ||||
A.I.dvisor indicates that over the last year, RLAY has been loosely correlated with CGEM. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RLAY jumps, then CGEM could also see price increases.
| Ticker / NAME | Correlation To RLAY | 1D Price Change % | ||
|---|---|---|---|---|
| RLAY | 100% | +1.32% | ||
| CGEM - RLAY | 48% Loosely correlated | -1.98% | ||
| IMVT - RLAY | 46% Loosely correlated | -2.31% | ||
| CABA - RLAY | 46% Loosely correlated | -7.32% | ||
| VIR - RLAY | 45% Loosely correlated | -5.41% | ||
| KYTX - RLAY | 45% Loosely correlated | -2.52% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TIIV | 28.77 | N/A | N/A |
| AAM Todd International Intrinsic Value ETF (TIIV) | |||
| SMAY | 26.40 | -0.50 | -1.85% |
| FT Vest U.S. Small Cap Moderate Buffer ETF - May (SMAY) | |||
| SCD | 14.28 | -0.38 | -2.59% |
| LMP Capital and Income Fund | |||
| GRPZ | 29.96 | -1.32 | -4.21% |
| Invesco S&P SmallCap 600 GARP ETF (GRPZ) | |||
| RING | 59.37 | -3.28 | -5.24% |
| iShares MSCI Global Gold Miners ETF (RING) | |||